Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    • News

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

  • Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    • News

Digital employee wellness platform experiences growth despite dwindling cash receipts

  • In News
  • October 19, 2021
  • Samantha Freidin
Digital employee wellness platform experiences growth despite dwindling cash receipts

Employee wellness has been at the forefront of employer’s minds since the pandemic pulled us out of the office and left us as tracksuit clad, makeup free recluses. At least in my case anyway. 

Digital employee wellness company Limeade (ASX: LME) has seen organisation wide growth indicated by their increase in headcount and operating cash outflows following the acquisition of TINYpulse, an employee feedback software company. The 18% increase in staff costs and 56% increase in R&D represent investment in the Company’s tech platform and expansion with TINYpulse. 

Despite cash receipts from customers taking a 32% dip to $16.1 million in comparison to the prior corresponding period, the Company is retaining their customers with cash and recurring subscription revenue remaining strong. Limeade’s top 20 customers on average have 19 months remaining on their contracts, an increase from 17 months at Q2 2021. 

Q4 is expected to yield strong growth and further contract signings. The Company also expects to launch a mid-market wellbeing offering in Q4. 

Limeade reported operating costs of $4.1 million. It is however worth noting that a large upfront enterprise subscription was paid in early October, increasing the operating outflows for the quarter ending 30 September, in preparation. 

The Company maintains their financial guidance for FY21 of $50-53 million in revenue and an EBITDA loss of $5-8 million, whilst maintaining a cash balance of $15.1 million and is debt free. They hold an undrawn debt facility of $15 million, representing headroom to pursue growth opportunities as they arise. 

One of those growth opportunities came in the form of a partnership with Microsoft Viva, an employee experience platform that can be accessed through Microsoft Teams. Limeade aims to ‘infuse care’ into digital platforms to foster better connections between teams and provide resources.  

CEO of Limeade, Henry Albrecht said: “During the quarter we focussed on serving our core enterprise well-being customers, integrating the TINYpulse acquisition and readying for the launch of an immersive well-being entry into the mid-market. Whether a company has 2000 or 20,000 employees, they seek to listen better and do more for their people to maximise business performance. We are very pleased at the acceleration of our late-stage enterprise sales pipeline to finalist, and verbal stages as well, providing Limeade with a solid platform for growth in 2022.”

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.